I Technology Transfer from Israeli Academy

Report
2nd Panel, Best Practices:
“IPR in Successful University-Industry Collaborations”
Dr. Tamar Raz, CEO
Hadasit, the Technology Transfer Company of
Hadassah Medical Organization (HMO), Jerusalem
Technology Transfer: Where Business Meet Science
Academic innovation is at the forefront of the Israeli
economy.
Israeli technology transfer companies promote the
transfer of academic-based technologies for the benefit
of society and have a direct contribution to the country’s
industrial and scientific success.
2
Technology Transfer from Israeli Academy - I
Technology Transfer from Israeli Academy - II
Mobileye
Cherry
Tomato
Hybrids
Pepper Hybrids
Sandisk Chip
Motorola Barcode
Reader
Polymerico
Fiber Optics
NDS Smart Card
Hadasit
Hadassah
100%
Corporate Structure
Established 1912
Established &
Incorporated 1986
Research in Hadassah
Hadassah is considered as a Center of
Excellence in research
60%
>2000
12
of the National Science Foundation Awards to biomedical research in Israeli hospitals
Scientific publications in the past 5 years
Winners of “Israel Prize” awards
Policies
University policies determine the way we work!
• Ownership policies on inventions (may involve government policy)
Israel, Patents Law, 1967
The Patents Law, 5727-1967
“Service Inventions”
(Chapter VIII, Article 132)
Employees’ invention belong to the Employer
• Clear university policies on:
– Sharing of royalties
– Publication, confidentiality
– Use of university resources by industry and particularly spin-outs
– Right of faculty to participate in spin-out companies, consulting
to industry, etc.
7
Core Expertise of Technology Transfer Organization
Licensing
 Technology scouting
Long
Term
 IP management
 Commercialization
Managing Relationship and
Interactions with Industry
Short
Term
 Marketing and support of clinical trials and pre-clinical services
Hadasit – Solid Reality and Potential upside
~ 200
ACTIVE PATENT
FAMILIES
Novel Therapeutics
Diagnostics
Medical devices
>40
46%
NEW ESTABLISHED
COMPANIES
ALREADY LICENSED
The technology Transfer process
Evaluation
Discovery
&
Innovation
Patenting &
Marketing
Strategy
Business
Development
Follow Up
on Contract
Research
Revenue Sharing:
40% - The inventor/s
20% - For Research
40% - The Institution
Revenues
Licensing Deal Models and Revenue Strategies
Research and
option
agreements
Research funds
Licensing deals licensing of IP and
know how to an
existing company
Fees and milestones
payments
Running royalties
Equity participation
New venture
formation licensing of IP
to a start-up
company
Hadasit Selected Partners
Hadasit Potential Upside Product Pipeline
Pre-clinical
Phase I / FIM
Phase II
Phase III
Launched
Proximab
Rehumatoid Arthritis
Protab (HBL)
ApoCell
GvHD; Hematol Malign.
Enlivex (HBL)
THR-18
Ischemic Stroke
D-Pharm (HBL)
StemEx
Hematological Cancers
GamidaCell
Doxil
Cancer
J&J
KAHR 102
Autoimmune , Cancer
KAHR (HBL)
MM-II
Osteoarthritis
Moebius Medical
MG01CI SR
ADD
Alcobra
InsuPad™/ InsuPatch™
Improved Insulin Uptake
Insuline Medical
Periochip
Dental Implants
Dexxon
OpRegen
Wet AMD
CellCure (HBL)
Hoodia
Diabetes Type II
PlantyLight
Oral Anti-CD3 Ab
NASH, HCV, Crohns
NasVax
13C-Methcetin
Travelan
Travelers’ diarrhea
Immuron
KAHR 101,
Autoimmune , Cancer
KAHR (HBL)
13C-Octanoate
13C-Urea
GI applications
Exalenz
IMM 124E
NASH, Diabetes type II
Immuron
Biocompatible Implant
Guided Bone Regeneration
RegeneCure
NiCord
Autoimmune Diseases
GamidaCell
BL-8040 (BKT140)
Hematological Cancers
BiolineRx & Biokine
Various Microscopes Nanoscale
Imaging
Nanonptics Imaging
IMM 308
C. Difficile
Immuron
ORMD0901
Oral Exantide (GLP-1)
OraMed
ORMD0801
Oral Insulin- diabetes
OraMed
Cord Blood Preservation
Various Uses
MediFreeze
Natural Antioxidants
CNS Disorders
Granalix
EHD
IMM 243
GI infections in HIV
Immuron
Bio-Therapy
Wound Healing (Larva)
CWT
BreathID
Early Hematoma Detection
B.R.F. & InfraScan
PET Agent for MPI
Cardiovascular diagnostics
Synektik
Liposomal Alendronate
Coronary artery stenosis
BioRest
pH Sensing Zonda
GI
Zonda Medical
HT100
DMD
Halo Therapeutics
BreathID
Liver dysfunction
Exalenz
BreathID
H. Pylori (gastric ulc)
Exalenz
Drugs & Molecules
Medical Devices
Diagnostics &
Services
Hadasit Golden Nuggets
Success Stories
DOXIL (J&J) - Doxorubicin HCL Liposomal Injection
Prof. Yechezkel Barenholz
Faculty of Medicine, HUJI
Prof. Alberto Gabizon
Hadassah Medical Center
DOXIL is used primarily to treat ovarian and breast cancer by
using a lipid-based formulation that has a cancer-killing drug
inside it.
Product Jointly Developed by Hebrew University & Hadassah
Hospital
Commercialized to ALZA – Bought By J&J
Worldwide sales of DOXIL in 2013 were about US$600 M, with
US$250 M coming from the US market.
Prof. Yaron Ilan
Immuron’s Chief
Medical Officer
Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on
oral immunotherapy using dairy-derived antibody products for humans.
Travelan® is a natural product which is specifically designed to
prevent Travellers’ Diarrhea.
IMM-124E is a natural product for the treatment of Fatty Liver
and NASH. Currently in phase II clinical trials.
Hadassah serves as Immuron’s clinical trials site and carried out
Immuron’s first successful proof of concept
Business Strategy and Main Challenges
Business Strategy - Key Points
 Excel in technology transfer by:
 Increasing the number and quality of available IP
 Sophisticated and state of the art license deals
 Develop partnerships between Hadassah inventors and the business
community by:
 Providing sponsored research opportunities and services to the
industrial community
 Main challenges
 Bridge the development gap – support new opportunities
 Active scouting / managing relationship with faculty staff
 Finding the right partners
Thank you.
For further information please contact
[email protected]

similar documents